Breakthrough in AML Treatment: New Drug Combination Shows Promising Results

Osaka Metropolitan University researchers have developed a groundbreaking treatment strategy for relapsed and refractory acute myeloid leukemia (AML), combining venetoclax and azacitidine to improve patient survival rates while reducing toxicity. This innovative approach, highlighted in the Blood Cancer Journal, shows that 66.7% of patients treated with this regimen survived after one year, compared to 27.3% in the control group. This advancement paves the way for safer and more effective therapies in the fight against AML.